The Oncology Institute

The Oncology Institute, Inc. provides cancer care treatment services. It offers evidence-based cancer care to patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. The company is headquartered in Cerritos, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The Oncology Institute reports strong revenue growth amidst operational challenges

TOI's Q1 2024 performance showcased robust revenue growth driven by strategic partnerships and record prescription sales, despite challenges with drug margin compression.
Operational achievements and a healthy cash position provide a strong foundation for TOI to navigate challenges and capitalize on growth opportunities in the oncology market.
By focusing on strategic priorities outlined by CEO Daniel Virnich, TOI aims to enhance profitability, expand market presence, and lead in value-based oncology care.

The Oncology Institute reports strong Q2 growth amid margin challenges

TOI's Q2 2024 earnings call reflected strong revenue growth but challenges with margins and profitability. The company is focused on addressing margin pressures and enhancing shareholder value through strategic initiatives.

The Oncology Institute reports robust Q3 growth and strategic focus

TOI's Q3 2024 performance reflects strong revenue growth, cost management, and strategic initiatives to drive operational efficiency and compliance.
The company's strengths lie in proactive cost optimization, expanded service offerings, and a clear strategic direction towards growth and performance.
Challenges include regulatory compliance, profitability sustainability, and ongoing efforts to balance financial flexibility with quality care delivery.
Opportunities abound in stable revenue streams, strategic partnerships, and enhanced profitability through optimized cost structures and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

The Oncology Institute, Inc. (TOI) Q4 2023 Earnings Call Transcript

CERRITOS, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2023.

The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024

The Oncology Institute (TOI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -23.64% in 4 Weeks, Here's Why The Oncology Institute (TOI) Looks Ripe for a Turnaround

TOI announces clinical and financial accountability for MaxHealth Oncology Care in 5 Florida Counties TOI announces clinical and financial accountability for MaxHealth Oncology Care in 5 Florida Counties

MaxHealth & The Oncology Institute Expand Value-Based Care Partnership

CERRITOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2023 financial results after the market close on Wednesday, March 27, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference Call

Value-based care program offers Las Vegas patients access to high quality cancer care while reducing costs for employers Value-based care program offers Las Vegas patients access to high quality cancer care while reducing costs for employers

Carrum Health and The Oncology Institute Partner on Breast Cancer Treatment Model

Delcath Systems

Nkarta, Inc.

Wave Life Sciences

As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.

Penny Stocks To Buy Now? 4 To Watch Before 2024

CERRITOS, Calif, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (TOI) announced today that it has started operations of its first pharmacy in California after receiving approval from the California State Board of Pharmacy. This new service allows TOI to fill not only critical specialty medications and chemotherapeutics for MediCal patients, but also to provide medication fill capabilities to other patient populations. Located in the Los Angeles area, this new pharmacy location comes in addition to the multiple integrated specialty medication dispensaries that TOI already uses to manage oral and injectable medications.

The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in California

The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Jack Slevin - Jefferies Operator Good afternoon, and welcome to The Oncology Institute Third Quarter 2023 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q3 2023 Earnings Call Transcript

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call

CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company.

The Oncology Institute Names Jeremy Castle as Chief Operations Officer

CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating in the Association for Value-Based Cancer Care (AVBCC) Summit.

The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit

CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today announced that it received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) on September 15, 2023, informing the Company that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. This follows second quarter 2023 results demonstrating continued strong year over year revenue growth, and announcements on recent technology partnerships with Ambience Healthcare and Massive Bio to drive continued efficiencies and expansion of the business.

The Oncology Institute Regains Compliance with Nasdaq Listing Requirements

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji Phillips - Jefferies Operator Good afternoon ladies and gentlemen and welcome to The Oncology Institute's Second Quarter 2023 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q2 2023 Earnings Call Transcript

CERRITOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ambience Healthcare, a market leader in generative AI technology for clinical documentation, workflows, and patient experience, and The Oncology Institute (TOI), a premier provider of cutting-edge cancer care, are announcing a landmark agreement to implement a new AI operating system for oncology care.

Ambience Healthcare and The Oncology Institute (TOI) Partner to Create a Best-in-Class Oncology Experience for Patients and Clinicians, Leveraging Breakthrough Generative AI Technology

CERRITOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2023 and reaffirmed its full year 2023 guidance.

The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance

CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after the market close on Tuesday, August 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call

Predictive Oncology Inc

The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.

3 Penny Stocks That Have Game-Changing Technologies

Dr. Daniel Virnich promoted from President to CEO. Brad Hively will transition from CEO to Vice Chairman. Dr. Daniel Virnich promoted from President to CEO. Brad Hively will transition from CEO to Vice Chairman.

The Oncology Institute Announces Leadership Transition

CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.

The Oncology Institute (TOI) and Massive Bio Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

TOI acquires SRON and expands radiation oncology services in the Greater LA area TOI acquires SRON and expands radiation oncology services in the Greater LA area

The Oncology Institute to Open Project Southland

NEW YORK--(BUSINESS WIRE)--Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network. Under this visionary collaboration, Massive Bio will support TOI.

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

CERRITOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, is featured on four authored abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting being held at the McCormick Place Convention Center in Chicago, Illinois June 2-6, 2023.

The Oncology Institute Featured on Four Abstracts at ASCO 2023 Annual Meeting

The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Brad Hively - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Brian Tanquilut - Jefferies Operator Good afternoon. Welcome to The Oncology Institute First Quarter 2023 Earnings Conference Call.

The Oncology Institute, Inc. (TOI) Q1 2023 Earnings Call Transcript

CERRITOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2023.

News for The Oncology Institute Stock (TOI)